GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clinuvel Pharmaceuticals Ltd (ASX:CUV) » Definitions » Total Long-Term Assets

Clinuvel Pharmaceuticals (ASX:CUV) Total Long-Term Assets : A$9.06 Mil (As of Jun. 2024)


View and export this data going back to 2001. Start your Free Trial

What is Clinuvel Pharmaceuticals Total Long-Term Assets?

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. Clinuvel Pharmaceuticals's Total Long-Term Assets for the quarter that ended in Jun. 2024 was A$9.06 Mil.

Clinuvel Pharmaceuticals Total Long-Term Assets Historical Data

The historical data trend for Clinuvel Pharmaceuticals's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clinuvel Pharmaceuticals Total Long-Term Assets Chart

Clinuvel Pharmaceuticals Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Total Long-Term Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.39 5.72 3.37 4.10 9.06

Clinuvel Pharmaceuticals Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Total Long-Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.37 3.48 4.10 10.18 9.06

Clinuvel Pharmaceuticals Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.

Clinuvel Pharmaceuticals Total Long-Term Assets Related Terms

Thank you for viewing the detailed overview of Clinuvel Pharmaceuticals's Total Long-Term Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Clinuvel Pharmaceuticals Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clinuvel Pharmaceuticals Ltd (ASX:CUV) » Definitions » Total Long-Term Assets
Comparable Companies
ASX:BOT ASX:OPT ASX:IMM ASX:PYCDA ASX:IMU ASX:RAC ASX:ALA ASX:DXB ASX:LTP ASX:OCC VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY BNTX XKRX:068270 BGNE
Traded in Other Exchanges
CLVLY:USA CLVLF:USA UR9:Germany UR9:Germany UR9:Germany
Address
535 Bourke Street, Level 22, Melbourne, VIC, AUS, 3000
Website
https://www.clinuvel.com
Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US.

Clinuvel Pharmaceuticals Headlines

No Headlines